Investor can buy Cipla at current level: Sukhani

Sukhani told CNBC-TV18, "Cipla has broadly disappointed over the last many years. It is exactly where it was around Rs 300 plus or minus. For Dishman Pharma there is a trade on the long side. After a very decent breakout, base building exercise, the stock has broken out. It is making new highs now and even at current levels I would say that if somebody is a positional trader or an investor, it is worth buying at current levels. For somebody who is a trader can even consider buying if there is a mild minor dip."